Herbal Approaches to Cholangiocarcinoma: A Systematic Review | Chapter 2 | Advanced Concepts in Medicine and Medical Research Vol. 11

Cholangiocarcinoma (CCA) is a diseased bile pipe cancer of epithelial containers with high depression and mortality. The increasing incidence of cholangiocarcinoma (hostility duct tumor) and limited treatment alternatives stimulate a urgent demand for research and the development of new chemotherapeutics against cholangiocarcinoma. This phase highlights the act of herbal cure in Cholangiocarcinoma control by using a systematic review approach. This study still aimed to orderly review herbs and herb-derivative compounds or herbal formulations that have existed investigated for their anti-cholangiocarcinoma potential. Orderly literature searches were attended in three electronic databases: PubMed, Skill Direct, and Scopus. The studies were initially secluded by titles and abstracts to exclude immaterial articles and duplication. Individual hundred and twenty-three research articles completed the eligibility tests and were included in the study (68 herbs, isolated compounds and/or artificial analogs, 9 herbal formulations, and 119 compounds that are commonly in the direction of several plant variety). The most examined herb was Atractylodes lancea (Thunb.) DC. (Compositae) and Curcuma longa L. (Zingiberaceae). Only A. lancea (Thunb.) DC. (Compositae) has sustained the full process of nonclinical and clinical evolve- ment to deliver the things produced for clinical use. The extracts of A. lancea (Thunb.) DC. (Compositae), Garcinia hanburyi Hook.f. (Clusiaceae), and Piper nigrum L. (Piperaceae) exhibit antiproliferative actions against human cholangiocarcinoma cells (IC50 < 15 µg/mL). Cucurbitacin B and triptolide are herbaceous isolated compounds that exhibit ultimate promising activities (IC50 < 1 µM). A order of experimental studies (artificial, in vivo, and humans) rooted the anti-cholangiocarcinoma potential and security profile of A. lancea (Thunb.) DC. (Compositae) and its alive compounds atractylodin and β- eudesmol, including the capsule drug of the standardized A. lancea (Thunb.) DC. (Compositae) extract. Future research endure focus on the complete development of the bidder herbs to deliver safe and productive products for cholangiocarcinoma control.Future research endure be geared toward the filled development of the applicant herbs until the delivery of ending products that are dependable and effective for CCA control.

Author(s) Details:

Kesara Na-Bangchang,
Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Chulabhorn International College of Medicine, Thammasat University (Rangsit Campus), Klongneung, Klongluang District, Pathumthani, Thailand and Drug Discovery and Development Center, Office of Advanced Science and Technology, Thammasat University (Rangsit Campus), Klongneung, Klongluang District, Pathumthani, Thailand.

Tullayakorn Plengsuriyakarn,
Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Chulabhorn International College of Medicine, Thammasat University (Rangsit Campus), Klongneung, Klongluang District, Pathumthani, Thailand.

Juntra Karbwang,
Drug Discovery and Development Center, Office of Advanced Science and Technology, Thammasat University (Rangsit Campus), Klongneung, Klongluang District, Pathumthani, Thailand.

Please see the link here: https://stm.bookpi.org/ACMMR-V11/article/view/12885